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Background: The optimal fractionation schedule of radiotherapy (RT) for Glioblastoma multiforme (GBM) is yet to
be determined. We aim to compare different fractionation regimens and identify prognostic factors to better tailor
RT for newly diagnosed GBM patients.
Methods: All data for patients who underwent surgery for GBM between January 2005 and December 2012 were
compiled. Clinical information was collected using patient charts and government registry. Cox analysis was used to
identify variables affecting survival and treatment outcome.
Results: The median follow-up time was 13.2 months. Two hundred and seventy-six patients met the inclusion
criteria, including 147 patients in the 60 Gy in 30 fractions (ConvRT) group, 86 patients in the 60 Gy in 20 fractions
(HF60) group, and 43 patients in the 40 Gy in 15 fractions (HF40) group. Median survival (MS) was 16.0 months with
a median progression-free survival (PFS) of 9.23 months in the ConvRT group. This was comparable to outcome in
the HF60 group with MS 15.0 months and a median PFS of 9.1 months. Patients in the HF40 group had MS of
8 months, with a median PFS 5.4 months. Cox analysis showed no significant difference in OS between the ConvRT
and HF60 groups but worse outcome in the HF40 group (HR 2.22, P = 0.04). MGMT methylation, extent of resection,
use of chemotherapy, and repeat surgery were found to be significant independent prognostic factors for survival.
Conclusions: HF60 constitutes a safe RT approach that shows survival comparable to standard RT while allowing
for a shorter treatment time.
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Glioblastoma multiforme (GBM) is the most lethal form
of primary brain tumor in adults. Maximal safe resec-
tion followed by radiotherapy (RT) with concomitant
and adjuvant temozolomide (TMZ) is the current stan-
dard of care [1,2]. O6-methylguanine-DNA methyltrans-
ferase (MGMT) is a DNA-repair protein that protects
GBM tumor cells against alkylating agents by removing
alkyl adducts from the O6-position of guanine [3].
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unless otherwise stated.significant prognostic biomarker, with a median survival
of 23.4 months for GBM patients with methylated
MGMT, compared to 12.6 months in the case of
unmethylated tumors [4].
The current standard RT regimen for GBM involves the
delivery of 60 Gy in 2.0 Gy per fraction, delivered over
6 weeks. Hypofractionation refers to the use of a fewer
number of larger sized fractions to reduce the overall
treatment time, limit tumor repopulation, and potentially
increase cell kill [5,6]. At this time, hypofractionation has
been administered mostly to patients over 65 years of age
and/or with poor performance status, patients who might
derive only limited benefit from combined chemoradiationl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gested that hypofractionated RT regimen could result in
survival comparable to conventional RT [9-12]. In a retro-
spective study, we reported on 35 patients who were
treated with a hypofractionated RT regimen while receiv-
ing concomitant and adjuvant TMZ [10]. The outcome
was comparable to the EORTC/NCIC data with a median
overall (OS) survival of 14.4 months and minimal toxicity.
A number of prospective trials have also reported on
the safety and efficacy of the hypofractionated approach
[13-16]. However, concerns over the potential toxicity
associated with a high dose, such as radionecrosis, have
hindered the adoption of hypofractionated RT. A pro-
spective study in the pre-TMZ era reported on the de-
livery of 50 Gy in 5 Gy/fraction daily to the enhancing
primary disease, residual tumor, and surgical cavity [13].
The outcome was comparable to the survival data at that
time, with a median OS of 7 months after treatment
completion. The development of intensity modulated ra-
diation therapy (IMRT) has allowed for more conformal
RT treatment with better dose modulation, thereby de-
creasing the risk of complications. Our group reported a
phase I trial that included 25 newly diagnosed GBM pa-
tients treated with hypofractionated IMRT and TMZ
[14]. The median survival was 15.67 months. More re-
cently, a phase II trial by Luchi et al. reported on their
use of a concomitant radiation boost of 68 Gy in 8 frac-
tions encompassing the surgical cavity and residual [15].
They did not report any neurological toxicity and the
median OS was 20.0 months.
The optimal fractionated RT regimen in GBM remains
to be determined, with the objective to improve local con-
trol and to reduce toxicity. Despite a number of studies
supporting the use of hypofractionated RT, the current
conventional RT regimen of 60 Gy in 2 Gy per fraction is
still the standard of care in GBM. Our study investigates
the benefits of hypofractionation in a population-based
cohort of patients diagnosed with GBM.
Materials and methods
Patient population
After obtaining GEN-Research Ethics Board ethics board
approval, we compiled a list of all adult patients who
underwent surgery for histologically-confirmed GBM bet-
ween January 2005 and December 2012. Patient in-
formation, tumor characteristics including MGMT status,
treatment details, and outcomes were obtained using
computerized hospital charts and patient registry. Of the
475 patients identified, a total of 342 patients received ad-
juvant RT, with or without concomitant TMZ. From this
group, 66 patients were excluded from the final analysis
for not having completed a curative RT treatment to a
dose of at least 40 Gy, having a history of prior cranial RT,
and/or having infra-tentorial GBM lesions.Patient management
All patient cases were reviewed by a multidisciplinary
group and offered surgery, adjuvant RT and/or chemo-
therapy. All tumors diagnosed as GBM were reviewed by
the neuropathologists.
Surgery
Maximum safe resection was performed by the neuro-
surgeon and was based on tumor location, extent of
disease, and on patient characteristics, which included
KPS, age, and co-morbidities. Presence of residual dis-
ease was assessed via gadolinium-enhanced MRI per-
formed at 48-72 hours post-operatively in close to 90%
of patients. Operative reports were used in cases where
imaging was not available.
Radiation treatment regimen
Patients were immobilized with a thermoplastic mask
for simulation and treatment. They underwent CT-based
planning with 3 mm slices. Co-registration of the post-
operative MRI was performed, when imaging was avail-
able. Enhancing residual disease, if present, as well as
the surgical cavity were contoured. A margin of 2 cm
was added with appropriate cropping to respect anato-
mical boundaries. For patients who received the hypo-
fractionated regimen, the treatment planning included
two planning target volumes (PTV): (i) PTV40 was de-
fined by adding a 1.5 cm margin on the GTV/cavity and it
received 40 Gy in 20 fractions; (ii) PTV60 was a concomi-
tant boost volume defined by adding a 0.5 cm margin on
the GTV/residual and it received a total dose 60 Gy in 20
fractions. Radiation treatment was planned using either
forward or inverse IMRT. In most cases, the PTV was
covered by the 95% isodose. Organs at risk including the
brainstem, optic chiasm, and optic nerves were contoured.
Dose to the brainstem and optic chiasm was limited to
less than 54 Gy for conventional fractionation. Dose con-
straints for the hypofractionated regimen were specified as
less than 40 Gy in 20 fractions to the brainstem, chiasm,
and at least one retina.
The following fractionation schedules were used: con-
ventional RT with 60 Gy in 30 fractions (ConvRT);
hypofractionated RT with 60 Gy in 20 fractions (HF60);
hypofractionated RT with 40 Gy in 15 fractions (HF40).
All the regimens were delivered 5 days per week. The
HF60 regimen excluded patients with T1 gadolinium
enhancement present at less than 1.5 cm from the brain-
stem and/or optic apparatus. Furthermore, patients over
the age of 70 or with KPS <70 usually received the HF40
regimen, as per current treatment guidelines [17].
Chemotherapy
The majority of patients received concomitant TMZ at a
dose of 75 mg/m2 daily during radiation treatment. This
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daily 5 days every 28 days, as per the NCIC regimen [1].
At the time of progression, patients were assessed for
second line chemotherapy, repeat surgery, and/or re-
irradiation.
Patient assessment and outcome
Patients were assessed weekly during RT with physical
examination, and bloods tests including complete blood
counts, serum electrolytes as well as renal and liver
function. After completion of RT, patients were assessed
on follow-up visit every three months with clinical
evaluation and MRI. Evaluation of tumor response was
determined based on imaging reports and review of the
MRI T1 enhanced and/or T2 images.
The date of recurrence was determined from the time
at which either progressive residual enhancement was
observed or new areas of disease appeared on imaging.
Progression free survival (PFS) was defined from the
date of diagnosis until the documentation of disease pro-
gression clinically and/or radiologically. Overall survival
(OS) was measured from date of diagnosis until date of
death, or date of last clinical follow-up visit.
Pseudoprogression was defined as radiological pro-
gression within three to six months of RT completion,
followed by stability or regression of the lesion without
the patient receiving treatment for recurrence. Patients
who had repeat surgery for presumed recurrence who
did not show evidence of persistent malignancy on
pathology were also deemed to have pseudoprogression.
The pattern of failure was deemed to be central if in
continuity with the initial tumor cavity, and distal if
more than 2 cm from the cavity.
Endpoints and statistical analysis
The primary endpoint of this retrospective study was OS
and the secondary endpoint was PFS. Statistical analysis
was carried out using SAS version 9.3 (SAS Institute,
Cary, NC, USA). Descriptive statistics were used to
summarize the study population. Univariate and multi-
variate Cox proportional hazard regression models were
used to assess the impact of different treatment regi-
mens on OS and PFS. The index date was date of death
for analyses of OS, and date of first progression for PFS.
The effect of treatment regimen on survival was quan-
tified by means of hazard ratios (HRs) with 95% confi-
dence intervals (95% CIs). Analyses were adjusted for
important prognostic factors for survival, such as KPS
(dichotomous: ≥ 70 versus 70), age (dichotomous: ≥ 65
versus <65), extent of initial surgery performed (biopsy
versus subtotal resection or gross total resection), having
any chemotherapy before the index date (dichotomous),
having repeated surgery before the index date and
methylation status of MGMT (methylated, unmethylatedand unknown). In order to investigate artificial diffe-
rences in survival caused by treatment based on age and
KPS status, we conducted sensitivity analyses of multi-
variate models, testing for the multiplicative interaction
terms between age and treatment group and between
KPS status and treatment group. Analyses were indepen-
dently repeated for each treatment group. We assessed
the assumption of proportional hazard by examining
graphs of scaled Schoenfeld residuals. Statistical signifi-
cance of Kaplan-Meyer curves was assessed by the log-




A total of 276 patients with histologically-proven GBM
who received adjuvant RT, with or without concomitant
TMZ, were included in this population-based study.
Overall median follow-up time was 13.2 months (range
1.4 to 105.7 months). Patient characteristics are summa-
rized in Table 1. One hundred and forty-seven patients
received ConvRT, 86 patients received hypofractionated
RT as per the HF60, and 43 patients as per the HF40
regimen. Two hundred and two patients were found to
have tumor progression on imaging. The median sur-
vival for the whole population was 13.7 months with a
median PFS of 8.8 months.
The similarities in patient characteristics between the
ConvRT and HF60 groups are in contrast to that of pa-
tients in the HF40 group. Patients in the ConvRT and
HF60 groups were more likely to have gross tumor re-
section (GTR), to have had repeat surgery at the time of
recurrence, and to have received chemotherapy at some
point during their treatment. Patients in the HF40 group
were older in age, with a median age of 72, and had a
more limited performance status, with close to half of
these patients having a KPS of less than 70.
Treatment regimen, OS and PFS
Median survival was 16 months in the ConvRT group and
15 months in the HF60 group (P = .3487, Figure 1a). Sur-
vival in the HF40 arm was significantly lower than
ConvRT with a median survival of 8 months (P < .00001).
This difference in survival was also sustained at 1 and
2 years after diagnosis, with a 2-year OS of 23.1% and
19.7% (P = .347) in the ConvRT and HF60 groups, respec-
tively. Compared to these results, the OS was extremely
poor in the HF40 group, with only 2.32% of patients still
alive at 2 years. Our data also showed that for patients
65 year and older, the median survival was 10.0 months in
the ConvRT group, compared to 9.13 (P = .357) for the
HF60 patients, and 7.6 months for the HF40 patients
(P = .0049). We did not find any indication in our cohort
of patients of an interaction between age and treatment
Table 1 Patient characteristics per treatment groups
Patients (n = 276)
60 Gy in 30 Fr 60 Gy in 20 Fr 40 Gy in 15 Fr P value
(n = 147) (n = 86) (n = 43)
Number % Number % Number %
Age
<65 114 77.6 68 79.1 8 18.6 <.0001
≥65 33 22.4 18 20.9 35 81.4
median 59 57 72
Sex
Female 55 37.4 34 39.5 20 46.5 0.562
Male 92 65.6 52 60.5 23 53.5
KPS
<70 7 4.7 10 11.6 20 46.5 <.0001
≥70 140 95.3 76 88.4 23 53.5
Focality
Multifocal 12 8.2 8 9.3 8 18.6 0.130
Unifocal 135 91.8 78 90.7 35 81.4
Extent of surgery
Biopsy 12 8.1 17 19.7 8 18.6 0.017
STR 98 66.6 45 52.3 30 63.7
GTR 37 25.1 24 27.9 5 11.6
Chemotherapy
Yes 141 95.2 85 98.8 24 55.8 <.0001
No 4 2.7 1 1.2 16 37.2
Unknown 2 1.3 0 0 3 6.9
Repeat surgery
Yes 49 33.3 20 23.2 2 4.6 0.001
No 98 66.7 66 76.7 41 93.4
MGMT
Methylated 60 40.8 25 29 16 37.2 0.031
Unmethylated 53 36.0 38 44.1 9 20.9
Unknown 34 23.2 23 26.7 18 41.8
Abbreviations: Fr Fractions, STR Subtotal resection, GTR Gross total resection, MGMT O6-methylguanine-DNA methyltransferase.
Azoulay et al. Radiation Oncology  (2015) 10:106 Page 4 of 9status (Wald Chi-squared test = 0.0261; p = 0.8717). We
detected a borderline significant interaction between KPS
score and treatment regimen group (Wald Chi-squared
test = 5.8949; p = 0.0525).
These trends were also observed in terms of PFS
(Figure 1b). Median PFS was close to 9 months in both the
ConvRT and the HF60 groups, compared to 5.4 months in
the HF40 groups (P = .0002). The PFS at 1 year was 37.4%
in the ConvRT group, 31.4% in the HF60 group (P = .6894)
and 7.0% in the HF40 group (P = .0007).
Prognostic factors associated with survival
Multivariate analysis showed that treatment regimen
(ConvRT and HF60), methylation status, use of chemo-therapy, extent of resection and repeat surgery at the time
of recurrence were the most significant independent prog-
nostic factors for survival (Table 2). There was no signifi-
cant difference in treatment outcome when HF60 was
compared to ConvRT (HR: 1.27, 95% CI, 0.93-1.74). This
finding is in contrast to the HF40 treatment group, which
showed significantly worse outcome (HR 2.22; 95% CI,
1.30 to 3.80).
Patients with MGMT promoter methylation showed
significantly better survival compared to unmethylated
patients (HR 0.46 95% CI, 0.33 to 0.64; P < .0001). This
was seen in both the HF60 and ConvRT treatment regi-
mens. There were no independent prognostic factor
identified in the 65 years-old and older subgroup of
Figure 1 Kaplan Meier curves comparing overall survival (a) and progression-free survival (b) between treatment regimens.
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lation was small (n = 86) and that MGMT status could
not be determined in half of these patients due to limi-
ted tissue sampling.
Extent of resection was also found to significantly
affect outcome. At the time of initial surgery, both STR
(HR 0.62; CI, 0.39-0.99; P = .048) and GTR (HR 0.39; CI,
0.22 to 0.67; P = .001) were found to be superior to
biopsy alone. The effect of repeat debulking surgery at
the time of recurrence was also found to correlate with
survival (HR 0.62; CI, 0.44 to 0.86; P = .005). Upon loo-
king at factors affecting individual treatment regimens,
we found that in both the ConvRT and HF60 groups,
methylation status, and extent of resection were the
most significant prognostic factors affecting OS (Table 3).
In addition, in the HF60 group, age, use of chemo-
therapy and repeat surgery also correlated with betteroutcome. In comparison to ConvRT, only performance
status significantly affected survival in the HF40 group.
Pseudoprogression was found to develop at a median
time of 3.8 months in 10.8% of patients. Patients who
developed pseudoprogression had a median survival of
25.16 months with a 2- year OS of 46.6%, vs. a median
survival of 13.4 months and a 2-year OS of 16.6% for
those who did not (P = .002). Pseudoprogression did not
show an association with either the MGMT methylation
status of the tumor (P = .4506) or the RT regimen re-
ceived (P = .70).
Impact of methylation of MGMT on survival and pattern
of recurrence
Methylation of MGMT promoter was found as an inde-
pendent prognostic factor for OS. On Kaplan-Meier ana-
lysis, median survival in the ConvRT group of patients
Table 2 Univariate and multivariate analysis of variables
affecting overall survival
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age
<65 1 1
≥65 2.14 (1.60-2.86) <.0001 1.25 (0.86-1.82) 0.235
KPS
<70 1 1
≥70 0.51 (0.35-0.74) 0.0004 0.67 (0.43-1.05) 0.078
Extent of surgery
Biopsy 1 1
STR 0.54 (0.38-0.79) 0.0013 0.62 (0.39-0.99) 0.048
GTR 0.36 (0.23-0.56) <.0001 0.39 (0.22-0.67) 0.001
Treatment
60 Gy/30 fr 1 1
60 Gy/20 fr 1.15 (0.86-1.56) 0.3475 1.27 (0.93-1.74) 0.126
40 Gy/15 fr 4.07 (2.75-6.04) <.0001 2.22 (1.30-3.80) 0.004
Chemotherapy
No 1 1
Yes 0.20 (0.12-0.34) <.0001 0.52 (0.28-0.99) 0.045
Repeat surgery
No 1 1
Yes 0.51 (0.38-0.70) <.0001 0.62 (0.44-0.86) 0.005
MGMT
Unmethylated 1 1
Methylated 0.53 (0.39-0.74) 0.0001 0.46 (0.33-0.64) <.0001
Abbreviations: HR Hazard ratio, CI Confident interval, FR Fractions, STR Subtotal
resection, GTR Gross total resection, MGMT O6-methylguanine-DNA
methyltransferase.
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13.4 months for unmethylated tumors (P = .001; Figure 2).
Similar results were seen in the HF60 group, with MS of
20.6 months for methylated tumors, vs. 13.6 months for
unmethylated tumors (P = .0325). In the HF40 group,
patients with methylated tumour had a median survival
of 10.2 months, compared to 7.9 months for unmethylated
tumours. The outcome of patients with methylated
(P = .674) or unmethylated MGMT (P = .891) was not
affected by the RT regimen being used.
The pattern of recurrence was evaluated and correlated
with the MGMT methylation status. We found that distal
recurrences were more frequently associated with MGMT
methylated tumors (P = .020). We have also identified a
trend for central recurrence to be more often linked to
unmethylated tumors (P = .070). However, both methy-
lated and unmethylated tumors were more likely to recur
centrally than to recur distally (P < .0001).Discussion
The combination of RT and TMZ followed by adjuvant
TMZ has allowed to improve outcome for GBM patients
[1]. Despite the modest improvement in survival, this
regimen involves a prolonged RT course for patients
with reduced life expectancy. For that reason, defining
the optimal RT regimen is necessary. In this population-
based study, we have compared two GBM treatment
regimens to the ConvRT schedule. This is the first ana-
lysis showing that GBM treatment with hypofractionated
RT (HF60) is associated with comparable outcome to
conventional Stupp regimen [1].
Our findings corroborate the impact on survival of
some prognostic factors that have been previously re-
ported [18-20]. Here, the MGMT methylation status was
found to be a strong independent prognostic factor for
survival regardless the type of regimen used (HF60 and
ConvRT). Another factor strongly associated with im-
proved outcome is the extent of the initial tumor resec-
tion [21-23]. We observed that maximal safe resection
correlates with improved outcome when compared to
biopsy (HR 0.39) or subtotal resection (HR 0.62). In
addition, the repeat surgery at the time of progression im-
proves patient outcome on multivariate analysis (HR 0.62).
Whether this is due to patient selection bias due to re-
operating mostly fit patients with more accessible tumors
should be considered.
Our own experience regarding the use of hypofractio-
nation dates back to 1994. A phase I-II trial was con-
ducted by Shenouda et al. using a concomitant boost
technique [24]. The treatment was equivalent to that of
published series with respect to toxicity and outcome at
that time. Sultanem et al. reported on 25 patients who
received 60 Gy in 20 fractions to the gross tumor
volume, with concurrent administration of 40 Gy in 20
fractions to the PTV [9]. The median survival was
9.5 months, with a 1-year survival rate of 40%, and me-
dian PFS of 5.2 months. Panet-Raymond et al. further
reported on this RT regimen, with the inclusion of con-
comitant and adjuvant TMZ [10]. These results were
comparable to the survival data from the NCIC/EORTC
study and from the present study, supporting the use of
hypofractionation as a valid RT regimen.
The optimal management for GBM in elderly patients
remains poorly defined due to the heterogeneity of this
population in terms of performance status, co-morbidity,
and treatment options [25]. Roa et al. reported that adju-
vant hypofractionated RT (dose of 40 Gy in 15 fractions)
without TMZ was associated with the same survi-
val when compared to conventionally fractionated RT
(60 Gy in 30 fractions) in elderly patients [26]. In con-
trast, the NORDIC randomized trial showed that hypo-
fractionated (34 Gy in 10 fractions) was superior to
conventionally fractionated RT in that group of patients
Table 3 Multivariate analysis of prognostic factor for OS in each treatment group
Treatment groups
60 Gy in 30 fr 60 Gy in 20 fr 40 Gy in 15 fr
HR 95% CI P value HR 95% CI P value HR 95% CI P value
Age
(≥65 vs. <65) 1.58 (0.94-2.65) 0.085 2.05 (1.04-4.06) 0.039 0.69 (0.18-2.60) 0.58
KPS
(≥70 vs <70) 1.52 (0.53-4.38) 0.443 0.63 (0.27-1.47) 0.285 0.27 (0.11-0.66) 0.004
Extent of surgery
(STR vs. biopsy) 0.47 (0.19-1.17) 0.103 0.62 (0.30-1.25) 0.179 1.29 (0.33-0.99) 0.713
(GTR vs. biopsy) 0.33 (0.12-0.90) 0.031 0.29 (0.13-0.66) 0.003 0.20 (0.04-1.15) 0.071
Chemotherapy
(Yes vs. no) 0.34 (0.10-1.12) 0.075 0.11 (0.01-0.97) 0.047 0.62 (0.24-1.62) 0.330
Repeat surgery
(Yes vs. no) 0.73 (0.48-1.12) 0.149 0.35 (0.18-0.69) 0.002 0.18 (0.02-1.89) 0.154
MGMT
(Methylated vs. unmethylated) 0.46 (0.29-0.72) 0.001 0.37 (0.20-0.68) 0.002 0.57 (0.18-1.78) 0.329
Abbreviations: FR Fractions, STR Subtotal resection, GTR Gross total resection, MGMT O6-methylguanine-DNA methyltransferase.
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dence for the use of hypofractionation in elderly GBM
patients to shorten treatment duration and overcome ra-
diation resistance [8,26-28]. In our practice, the ConvRT
and HF60 regimens are generally offered to patients with
good performance status who underwent maximum safe
resection. This approach yields good results, with better
OS compared to treatment with the HF40 regimen, in-
cluding for patients 65 years of age or older. Admittedly,
the HF40 regimen is typically offered to patient with
poor KPS and limited tumor resection, factors that could
predict worse survival. However, our multivariate ana-
lysis which controlled for these factors showed thatFigure 2 Kaplan Meier cure for overall survival showing 2 fractionation regpatients receiving the HF40 regimen are twice more
likely to die compared to ConvRT. These findings sup-
port that a more radical approach can be considered for
selected elderly GBM patients with good performance
status and limited comorbidities [25,29].
The outcome of patients receiving ConvRT can be
compromised by tumor repopulation [30]. It has been
suggested that hypofractionation can be more effective
from a radiobiological standpoint to overcome the radio-
resistance of GBM cells. It has the dual effects of in-
creasing cell death from a higher dose per fraction, and
reducing the effect of tumor repopulation [6]. The bio-
logical effective dose (BED) is used to clinically compareimens based on the methylation status of the MGMT promoter.
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Assuming an α/β of 3 for late responding neural tissue
and α/β of 10 for tumor cells, the BED3 for the ConvRT
regimen would be 100 Gy with a BED10 of 72 Gy, for
GBM tumor cells. For the HF60 regimen, the BED3
would be 120 Gy and the BED10 would be 78 Gy. The
BED for the HF40 regimen is much lower, with a BED3
of 75 Gy and a BED10 of 50.5 Gy. While the HF60 shows
a higher BED for tumor cells, our own comparison did
not demonstrate the superiority of the hypofractionated
RT approach compared to ConvRT in terms of OS.
More investigation is needed to better evaluate which
fractionation regimen and dose, delivered in the pre-
sence of concomitant TMZ, could potentially overcome
the inherent radioresistance of GBM cells [31].
We acknowledge the limitations of the present study,
including the lack of data regarding long-term treatment-
related toxicity, as well as the heterogeneity of the treat-
ment groups, which reflects the population-based nature
of our study. Based on our experience using IMRT-based
HF60 over the last 10 years, cases of radiation-induced
toxicities have been rare, with most patients tolerating
hypofractionated RT in combination with TMZ without
complications. The use of advanced delivery technologies,
such as IMRT and image-guided RT, have allowed for
more conformal treatment delivery, thereby decreasing
the risk of serious long-term toxicities. Furthermore, the
potential benefits in terms of reduction of the financial
burden on the health care system and improved quality of
life for patients from a shortened course of RT should not
be neglected.
In conclusion, moderate hypofractionated RT (HF60) is
associated with comparable outcome to conventional RT
regimen for newly diagnosed GBM patients. Our study
also confirms the prognostic value of several factors, in-
cluding MGMT promoter methylation and re-operation
at the time of recurrence. However, the optimal treatment
for elderly population remains elusive and more research
is necessary to better adapt treatment for these patients.
Identification of biomarkers of responsiveness to hypo-
fractionation is necessary to better tailor treatment in
newly diagnosed GBM patients.
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